English
简体中文
Total: £ 56.28
Published Date: 2024-04-07 | Pages: 144 | Tables: 256 | Pharma & Healthcare
Haemophilus parasuis disease, also known as Grazer's disease, is an upper respiratory infectious disease of pigs caused by Haemophilus parasuis (HPS), mainly infecting piglets before and after weaning, clinically manifested as multiple fibrosis Serositis, arthritis and meningitis. The inactivated vaccine against Haemophilus parasuis can effectively prevent Haemophilus parasuis and reduce the mortality rate of Haemophilus parasuis infection.
The global market for Haemophilus Parasuis Bivalent Vaccine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Haemophilus Parasuis Bivalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Haemophilus Parasuis Bivalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Haemophilus Parasuis Bivalent Vaccine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Haemophilus Parasuis Bivalent Vaccine include Zoetis, Boehringer-Ingelheim, Eurovet, Hipra, Nisseiken, Merck Animal Health, SPAH, Pulike Biological Engineering and China Animal Husbandry Industry, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Haemophilus Parasuis Bivalent Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Haemophilus Parasuis Bivalent Vaccine by region & country, by Type, and by Application.
The Haemophilus Parasuis Bivalent Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Haemophilus Parasuis Bivalent Vaccine.
Market Segmentation
By Company
Zoetis
Boehringer-Ingelheim
Eurovet
Hipra
Nisseiken
Merck Animal Health
SPAH
Pulike Biological Engineering
China Animal Husbandry Industry
Wuhan Keqian Biology
Wo Hua Biotech
Zhejiang Ceva Ebvac Biotech
Luoyang Huizhong Biotech
Beijing Centrebio Biology
Shandong Huahong Bioengineering
Ringpu
Segment by Type:
Bivalent Inactivated Vaccine
Trivalent Inactivated Vaccine
Quadrivalent Inactivated Vaccine
Segment by Application
Piglets
Adults Pigs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Haemophilus Parasuis Bivalent Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Haemophilus Parasuis Bivalent Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Haemophilus Parasuis Bivalent Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Haemophilus Parasuis Bivalent Vaccine Product Introduction
1.2 Global Haemophilus Parasuis Bivalent Vaccine Market Size Forecast
1.2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030)
1.2.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume (2019-2030)
1.2.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Price (2019-2030)
1.3 Haemophilus Parasuis Bivalent Vaccine Market Trends & Drivers
1.3.1 Haemophilus Parasuis Bivalent Vaccine Industry Trends
1.3.2 Haemophilus Parasuis Bivalent Vaccine Market Drivers & Opportunity
1.3.3 Haemophilus Parasuis Bivalent Vaccine Market Challenges
1.3.4 Haemophilus Parasuis Bivalent Vaccine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Haemophilus Parasuis Bivalent Vaccine Players Revenue Ranking (2023)
2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Company (2019-2024)
2.3 Global Haemophilus Parasuis Bivalent Vaccine Players Sales Volume Ranking (2023)
2.4 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Company Players (2019-2024)
2.5 Global Haemophilus Parasuis Bivalent Vaccine Average Price by Company (2019-2024)
2.6 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Haemophilus Parasuis Bivalent Vaccine
2.9 Haemophilus Parasuis Bivalent Vaccine Market Competitive Analysis
2.9.1 Haemophilus Parasuis Bivalent Vaccine Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Haemophilus Parasuis Bivalent Vaccine Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilus Parasuis Bivalent Vaccine as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Bivalent Inactivated Vaccine
3.1.2 Trivalent Inactivated Vaccine
3.1.3 Quadrivalent Inactivated Vaccine
3.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type
3.2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Value, by Type (2019-2030)
3.2.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Value, by Type (%) (2019-2030)
3.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type
3.3.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume, by Type (2019-2030)
3.3.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume, by Type (%) (2019-2030)
3.4 Global Haemophilus Parasuis Bivalent Vaccine Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Piglets
4.1.2 Adults Pigs
4.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application
4.2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Value, by Application (2019-2030)
4.2.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Value, by Application (%) (2019-2030)
4.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application
4.3.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume, by Application (2019-2030)
4.3.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume, by Application (%) (2019-2030)
4.4 Global Haemophilus Parasuis Bivalent Vaccine Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region
5.1.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2019-2024)
5.1.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2025-2030)
5.1.4 Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (%), (2019-2030)
5.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region
5.2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2019-2024)
5.2.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2025-2030)
5.2.4 Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (%), (2019-2030)
5.3 Global Haemophilus Parasuis Bivalent Vaccine Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
5.4.2 North America Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
5.5.2 Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
5.6.2 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
5.7.2 South America Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
5.8.2 Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value
6.2.1 Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.2.2 Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.3.2 United States Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.4.2 Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.5.2 China Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.5.3 China Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.6.2 Japan Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.7.2 South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.8.2 Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019-2030
6.9.2 India Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
6.9.3 India Haemophilus Parasuis Bivalent Vaccine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Company Information
7.1.2 Zoetis Introduction and Business Overview
7.1.3 Zoetis Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Zoetis Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.1.5 Zoetis Recent Development
7.2 Boehringer-Ingelheim
7.2.1 Boehringer-Ingelheim Company Information
7.2.2 Boehringer-Ingelheim Introduction and Business Overview
7.2.3 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.2.5 Boehringer-Ingelheim Recent Development
7.3 Eurovet
7.3.1 Eurovet Company Information
7.3.2 Eurovet Introduction and Business Overview
7.3.3 Eurovet Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Eurovet Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.3.5 Eurovet Recent Development
7.4 Hipra
7.4.1 Hipra Company Information
7.4.2 Hipra Introduction and Business Overview
7.4.3 Hipra Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hipra Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.4.5 Hipra Recent Development
7.5 Nisseiken
7.5.1 Nisseiken Company Information
7.5.2 Nisseiken Introduction and Business Overview
7.5.3 Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.5.5 Nisseiken Recent Development
7.6 Merck Animal Health
7.6.1 Merck Animal Health Company Information
7.6.2 Merck Animal Health Introduction and Business Overview
7.6.3 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.6.5 Merck Animal Health Recent Development
7.7 SPAH
7.7.1 SPAH Company Information
7.7.2 SPAH Introduction and Business Overview
7.7.3 SPAH Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.7.4 SPAH Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.7.5 SPAH Recent Development
7.8 Pulike Biological Engineering
7.8.1 Pulike Biological Engineering Company Information
7.8.2 Pulike Biological Engineering Introduction and Business Overview
7.8.3 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.8.5 Pulike Biological Engineering Recent Development
7.9 China Animal Husbandry Industry
7.9.1 China Animal Husbandry Industry Company Information
7.9.2 China Animal Husbandry Industry Introduction and Business Overview
7.9.3 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.9.4 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.9.5 China Animal Husbandry Industry Recent Development
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Company Information
7.10.2 Wuhan Keqian Biology Introduction and Business Overview
7.10.3 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.10.5 Wuhan Keqian Biology Recent Development
7.11 Wo Hua Biotech
7.11.1 Wo Hua Biotech Company Information
7.11.2 Wo Hua Biotech Introduction and Business Overview
7.11.3 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.11.5 Wo Hua Biotech Recent Development
7.12 Zhejiang Ceva Ebvac Biotech
7.12.1 Zhejiang Ceva Ebvac Biotech Company Information
7.12.2 Zhejiang Ceva Ebvac Biotech Introduction and Business Overview
7.12.3 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.12.5 Zhejiang Ceva Ebvac Biotech Recent Development
7.13 Luoyang Huizhong Biotech
7.13.1 Luoyang Huizhong Biotech Company Information
7.13.2 Luoyang Huizhong Biotech Introduction and Business Overview
7.13.3 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.13.5 Luoyang Huizhong Biotech Recent Development
7.14 Beijing Centrebio Biology
7.14.1 Beijing Centrebio Biology Company Information
7.14.2 Beijing Centrebio Biology Introduction and Business Overview
7.14.3 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.14.5 Beijing Centrebio Biology Recent Development
7.15 Shandong Huahong Bioengineering
7.15.1 Shandong Huahong Bioengineering Company Information
7.15.2 Shandong Huahong Bioengineering Introduction and Business Overview
7.15.3 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.15.5 Shandong Huahong Bioengineering Recent Development
7.16 Ringpu
7.16.1 Ringpu Company Information
7.16.2 Ringpu Introduction and Business Overview
7.16.3 Ringpu Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Ringpu Haemophilus Parasuis Bivalent Vaccine Product Offerings
7.16.5 Ringpu Recent Development
8 Industry Chain Analysis
8.1 Haemophilus Parasuis Bivalent Vaccine Industrial Chain
8.2 Haemophilus Parasuis Bivalent Vaccine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Haemophilus Parasuis Bivalent Vaccine Sales Model
8.5.2 Sales Channel
8.5.3 Haemophilus Parasuis Bivalent Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Haemophilus Parasuis Bivalent Vaccine Market Trends
Table 2. Haemophilus Parasuis Bivalent Vaccine Market Drivers & Opportunity
Table 3. Haemophilus Parasuis Bivalent Vaccine Market Challenges
Table 4. Haemophilus Parasuis Bivalent Vaccine Market Restraints
Table 5. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Company (2019-2024)
Table 7. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Company (2019-2024) & (K Doses)
Table 8. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Haemophilus Parasuis Bivalent Vaccine Price by Company (2019-2024) & (US$/Dose)
Table 10. Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Haemophilus Parasuis Bivalent Vaccine Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Haemophilus Parasuis Bivalent Vaccine
Table 13. Global Haemophilus Parasuis Bivalent Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilus Parasuis Bivalent Vaccine as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Doses)
Table 22. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type (2019-2024) & (K Doses)
Table 23. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type (2025-2030) & (K Doses)
Table 24. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Haemophilus Parasuis Bivalent Vaccine Price by Type (2019-2024) & (US$/Dose)
Table 27. Global Haemophilus Parasuis Bivalent Vaccine Price by Type (2025-2030) & (US$/Dose)
Table 28. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Doses)
Table 34. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application (2019-2024) & (K Doses)
Table 35. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application (2025-2030) & (K Doses)
Table 36. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Haemophilus Parasuis Bivalent Vaccine Price by Application (2019-2024) & (US$/Dose)
Table 39. Global Haemophilus Parasuis Bivalent Vaccine Price by Application (2025-2030) & (US$/Dose)
Table 40. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2019-2024) & (%)
Table 44. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Region (2025-2030) & (%)
Table 45. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (K Doses): 2019 VS 2023 VS 2030
Table 46. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2019-2024) & (K Doses)
Table 47. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2025-2030) & (K Doses)
Table 48. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2019-2024) & (%)
Table 49. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Region (2025-2030) & (%)
Table 50. Global Haemophilus Parasuis Bivalent Vaccine Average Price by Region (2019-2024) & (US$/Dose)
Table 51. Global Haemophilus Parasuis Bivalent Vaccine Average Price by Region (2025-2030) & (US$/Dose)
Table 52. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Volume, (2019-2024) & (K Doses)
Table 56. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Volume, (2025-2030) & (K Doses)
Table 57. Zoetis Company Information
Table 58. Zoetis Introduction and Business Overview
Table 59. Zoetis Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 60. Zoetis Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 61. Zoetis Recent Development
Table 62. Boehringer-Ingelheim Company Information
Table 63. Boehringer-Ingelheim Introduction and Business Overview
Table 64. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 65. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 66. Boehringer-Ingelheim Recent Development
Table 67. Eurovet Company Information
Table 68. Eurovet Introduction and Business Overview
Table 69. Eurovet Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 70. Eurovet Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 71. Eurovet Recent Development
Table 72. Hipra Company Information
Table 73. Hipra Introduction and Business Overview
Table 74. Hipra Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 75. Hipra Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 76. Hipra Recent Development
Table 77. Nisseiken Company Information
Table 78. Nisseiken Introduction and Business Overview
Table 79. Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 80. Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 81. Nisseiken Recent Development
Table 82. Merck Animal Health Company Information
Table 83. Merck Animal Health Introduction and Business Overview
Table 84. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 85. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 86. Merck Animal Health Recent Development
Table 87. SPAH Company Information
Table 88. SPAH Introduction and Business Overview
Table 89. SPAH Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 90. SPAH Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 91. SPAH Recent Development
Table 92. Pulike Biological Engineering Company Information
Table 93. Pulike Biological Engineering Introduction and Business Overview
Table 94. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 95. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 96. Pulike Biological Engineering Recent Development
Table 97. China Animal Husbandry Industry Company Information
Table 98. China Animal Husbandry Industry Introduction and Business Overview
Table 99. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 100. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 101. China Animal Husbandry Industry Recent Development
Table 102. Wuhan Keqian Biology Company Information
Table 103. Wuhan Keqian Biology Introduction and Business Overview
Table 104. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 105. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 106. Wuhan Keqian Biology Recent Development
Table 107. Wo Hua Biotech Company Information
Table 108. Wo Hua Biotech Introduction and Business Overview
Table 109. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 110. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 111. Wo Hua Biotech Recent Development
Table 112. Zhejiang Ceva Ebvac Biotech Company Information
Table 113. Zhejiang Ceva Ebvac Biotech Introduction and Business Overview
Table 114. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 115. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 116. Zhejiang Ceva Ebvac Biotech Recent Development
Table 117. Luoyang Huizhong Biotech Company Information
Table 118. Luoyang Huizhong Biotech Introduction and Business Overview
Table 119. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 120. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 121. Luoyang Huizhong Biotech Recent Development
Table 122. Beijing Centrebio Biology Company Information
Table 123. Beijing Centrebio Biology Introduction and Business Overview
Table 124. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 125. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 126. Beijing Centrebio Biology Recent Development
Table 127. Shandong Huahong Bioengineering Company Information
Table 128. Shandong Huahong Bioengineering Introduction and Business Overview
Table 129. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 130. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 131. Shandong Huahong Bioengineering Recent Development
Table 132. Ringpu Company Information
Table 133. Ringpu Introduction and Business Overview
Table 134. Ringpu Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 135. Ringpu Haemophilus Parasuis Bivalent Vaccine Product Offerings
Table 136. Ringpu Recent Development
Table 137. Key Raw Materials Lists
Table 138. Raw Materials Key Suppliers Lists
Table 139. Haemophilus Parasuis Bivalent Vaccine Downstream Customers
Table 140. Haemophilus Parasuis Bivalent Vaccine Distributors List
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Haemophilus Parasuis Bivalent Vaccine Product Picture
Figure 2. Global Haemophilus Parasuis Bivalent Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume (2019-2030) & (K Doses)
Figure 5. Global Haemophilus Parasuis Bivalent Vaccine Sales Price (2019-2030) & (US$/Dose)
Figure 6. Haemophilus Parasuis Bivalent Vaccine Report Years Considered
Figure 7. Global Haemophilus Parasuis Bivalent Vaccine Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Haemophilus Parasuis Bivalent Vaccine Players Sales Volume Ranking (2023) & (K Doses)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Haemophilus Parasuis Bivalent Vaccine Revenue in 2023
Figure 10. Haemophilus Parasuis Bivalent Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Bivalent Inactivated Vaccine Picture
Figure 12. Trivalent Inactivated Vaccine Picture
Figure 13. Quadrivalent Inactivated Vaccine Picture
Figure 14. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Haemophilus Parasuis Bivalent Vaccine Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Doses)
Figure 17. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Haemophilus Parasuis Bivalent Vaccine Price by Type (2019-2030) & (US$/Dose)
Figure 19. Product Picture of Piglets
Figure 20. Product Picture of Adults Pigs
Figure 21. Global Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Haemophilus Parasuis Bivalent Vaccine Sales Value Market Share by Application, 2023 & 2030
Figure 23. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Doses)
Figure 24. Global Haemophilus Parasuis Bivalent Vaccine Sales Volume Market Share by Application, 2023 & 2030
Figure 25. Global Haemophilus Parasuis Bivalent Vaccine Price by Application (2019-2030) & (US$/Dose)
Figure 26. North America Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 27. North America Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 28. Europe Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 29. Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 30. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 32. South America Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 33. South America Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 34. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Value (2019-2030) & (US$ Million)
Figure 35. Middle East & Africa Haemophilus Parasuis Bivalent Vaccine Sales Value by Country (%), 2023 VS 2030
Figure 36. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Value (%), (2019-2030)
Figure 37. Key Countries/Regions Haemophilus Parasuis Bivalent Vaccine Sales Volume (%), (2019-2030)
Figure 38. United States Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 39. United States Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 40. United States Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 41. Europe Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 42. Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 43. Europe Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 44. China Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 45. China Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 46. China Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 47. Japan Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 48. Japan Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 49. Japan Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 50. South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 51. South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 52. South Korea Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 53. Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 54. Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 55. Southeast Asia Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 56. India Haemophilus Parasuis Bivalent Vaccine Sales Value, (2019-2030) & (US$ Million)
Figure 57. India Haemophilus Parasuis Bivalent Vaccine Sales Value by Type (%), 2023 VS 2030
Figure 58. India Haemophilus Parasuis Bivalent Vaccine Sales Value by Application (%), 2023 VS 2030
Figure 59. Haemophilus Parasuis Bivalent Vaccine Industrial Chain
Figure 60. Haemophilus Parasuis Bivalent Vaccine Manufacturing Cost Structure
Figure 61. Channels of Distribution (Direct Sales, and Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
